Christoph Franz - Roche Holding Non-Executive Director
RHHBF Stock | USD 275.03 7.20 2.69% |
Director
Dr. Christoph Franz was NonExecutive Independent Chairman of the Board of Roche Holding Ltd since March 1, 2011. He is Member of the Remuneration Committee and Chairman of the PresidiumNomination Committee at the Company. He began his career in 1991 with Deutsche Lufthansa AG. In 1994 he joined Deutsche Bahn AG and acted as Member of the Executive Board and CEO of passenger transport division. In 2004 he became Chief Executive Officer of Swiss International Air Lines AG. In 2009 Dr. Franz became Member of the Executive Board of Deutsche Lufthansa AG and Deputy to the Executive Board Chairman and CEO Lufthansa Passenger Airlines. Since January 2011 he was Chairman of the Executive Board and Chief Executive Officer of Deutsche Lufthansa AG. He holds a Doctorate degree from Technische Universitaet Darmstadt . since 2011.
Age | 58 |
Tenure | 13 years |
Phone | 41 61 688 11 11 |
Web | https://www.roche.com |
Roche Holding Management Efficiency
The company has return on total asset (ROA) of 0.1468 % which means that it generated a profit of $0.1468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4483 %, meaning that it generated $0.4483 on every $100 dollars invested by stockholders. Roche Holding's management efficiency ratios could be used to measure how well Roche Holding manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
Diane Souza | Sanofi ADR | 65 | |
Ken Araki | Santen Pharmaceutical Co | N/A | |
Belen Morenes | Grifols SA ADR | 45 | |
Ann Cairns | AstraZeneca PLC ADR | 57 | |
Peter Voser | Roche Holding Ltd | 59 | |
Patrick Kron | Sanofi ADR | 64 | |
Tomas Gelabert | Grifols SA ADR | N/A | |
Baroness Vadera | AstraZeneca PLC ADR | 52 | |
Charles Bancroft | GlaxoSmithKline PLC ADR | 61 | |
Vivienne Cox | GlaxoSmithKline PLC ADR | 61 | |
Kanoko Ohishi | Santen Pharmaceutical Co | 57 | |
Iain Mackay | GlaxoSmithKline PLC ADR | 62 | |
Satoshi Suzuki | Santen Pharmaceutical Co | N/A | |
Ton Buechner | Novartis AG ADR | 55 | |
Weiying Wang | AstraZeneca PLC ADR | N/A | |
Frances Fergusson | Pfizer Inc | 71 | |
Suet Lee | Sanofi ADR | 60 | |
Urs Rohner | GlaxoSmithKline PLC ADR | 60 | |
Akihiro Tsujimura | Santen Pharmaceutical Co | 50 | |
Roy Anderson | GlaxoSmithKline PLC ADR | 69 | |
Atsutoshi Ohta | Santen Pharmaceutical Co | N/A |
Management Performance
Return On Equity | 0.45 | |||
Return On Asset | 0.15 |
Roche Holding AG Leadership Team
Elected by the shareholders, the Roche Holding's board of directors comprises two types of representatives: Roche Holding inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Roche. The board's role is to monitor Roche Holding's management team and ensure that shareholders' interests are well served. Roche Holding's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Roche Holding's outside directors are responsible for providing unbiased perspectives on the board's policies.
Barbara Schadler, Head Communications | ||
Osamu Nagayama, Member of the Enlarged Corporate Executive Committee and Presidentident and CEO of Chugai | ||
Michael Varney, Member of the Enlarged Corporate Executive Committee, Head Genetech Research and Early Development | ||
Bruno Eschli, Head Relations | ||
Silvia Ayyoubi, Head of Group HR | ||
Sophie KornowskiBonnet, Member of the Enlarged Corporate Executive Committee, Head of Roche Partnering | ||
Thomas Schinecker, Chief Diagnostics | ||
Beatrice Mauro, Non-Executive Director | ||
Cristina Wilbur, Member of the Executive Committee, Head Group Human Resources | ||
William Anderson, Member of the Corporate Executive Committee, CEO Roche Pharmaceuticals | ||
Roland Diggelmann, Member of the Corporate Executive Committee, COO of the Division Roche Diagnostics | ||
James Sabry, Member of the Enlarged Corporate Executive Committee, Global Head Pharma Partnering | ||
Gottlieb Keller, General Counsel and Corporate Secretary | ||
Urs Jaisli, Chief Compliance Officer | ||
Daniel ODay, COO of Pharmaceuticals division | ||
Claudia Bockstiegel, G Counsel | ||
DeAnne Julius, Non-Executive Director | ||
Johannes MD, Head Devel | ||
Karl Mahler, Head of Investor Relations | ||
Andre Hoffmann, Non-Executive Vice Chairman of the Board | ||
John Reed, Member of the Enlarged Corporate Executive Committee, Head of Roche Pharma Research & Early Development | ||
Claudia Dyckerhoff, Non-Executive Director | ||
Fritz Gerber, Honorary Chairman of the Board | ||
Stephan Feldhaus, Member of the Enlarged Corporate Executive Committee, Head Group Communications | ||
Julie Brown, Non-Executive Director | ||
Richard Lifton, Non-Executive Director | ||
Paul Bulcke, Non-Executive Director | ||
Christoph Franz, Non-Executive Director | ||
PerOlof Attinger, Secretary to the Corporate Executive Committee, Head CEO Office | ||
Pascale Schmidt, Chief Officer | ||
Pius Baschera, Non-Executive Director | ||
Peter Voser, Non-Executive Director | ||
Bernard Poussot, Non-Executive Director | ||
John Bell, Non-Executive Director | ||
Andreas Oeri, Non-Executive Director | ||
Alan Hippe, CFO and IT Officer | ||
William Pao, Member of the Enlarged Corporate Executive Committee, Head Roche Pharma Research & Early Development (pRED) | ||
F Hoffmann, IR Contact Officer | ||
Severin Schwan, CEO and Director | ||
Anita Hauser, Non-Executive Director | ||
Michael Heuer, Member of the Corporate Executive Committee, Interim CEO Roche Diagnostics |
Roche Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Roche Holding a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.45 | |||
Return On Asset | 0.15 | |||
Profit Margin | 0.19 % | |||
Operating Margin | 0.32 % | |||
Current Valuation | 287.91 B | |||
Shares Outstanding | 106.69 M | |||
Shares Owned By Insiders | 75.31 % | |||
Shares Owned By Institutions | 8.56 % | |||
Price To Earning | 21.63 X | |||
Price To Book | 11.61 X |
Currently Active Assets on Macroaxis
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Roche Holding AG. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Roche Holding AG information on this page should be used as a complementary analysis to other Roche Holding's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for Roche OTC Stock analysis
When running Roche Holding's price analysis, check to measure Roche Holding's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Roche Holding is operating at the current time. Most of Roche Holding's value examination focuses on studying past and present price action to predict the probability of Roche Holding's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Roche Holding's price. Additionally, you may evaluate how the addition of Roche Holding to your portfolios can decrease your overall portfolio volatility.
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |